NCT03430518 - Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2018

Primary Completion Date

February 10, 2020

Study Completion Date

February 10, 2020

Conditions

HER2-Negative Metastatic Breast CancerRecurrent Ovarian Cancer

Interventions

DRUG

Durvalumab

1.12g given IV on day 1 every 21 day cycle

DRUG

Eribulin

1.1 mg/m2 IV on day 8 of every 21 day cycle in the first 3 patients, then increased to 1.4mg/m2 IV on day 1 and day 8 of every 21 day cycle. If significant toxicity occurs in patients given the 1.1mg/m2 IV dose, then subsequent patients with receive eribulin 0.7mg/m2 IV on day 1 and day 8 of every 21 day cycle.

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York